Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is uniquely characterized by its primary biliary/gastrointestinal excretion rather than renal clearance.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
Standard dose: 5 mg orally once daily.
Maximum dose: 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients <18 years of age. Use is not recommended in the pediatric population.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Geriatric:** No dose adjustment required based on age.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* History of diabetic ketoacidosis (type 1 diabetes).
## Adverse Effects
* **Common:** Nasopharyngitis, upper respiratory tract infection, headache.
* **Serious:** Acute pancreatitis (discontinue if suspected), bullous pemphigoid (may require topical or systemic immunosuppressive therapy), severe and disabling arthralgia, hypersensitivity reactions.
## Key Drug Interactions
* **Strong P-glycoprotein/CYP3A4 Inducers (e.g., rifampin):** May decrease linagliptin efficacy. If co-administration is necessary, monitor glycemic control closely.
* **Insulin/Insulin Secretagogues (e.g., sulfonylureas):** Potential for increased risk of hypoglycemia; a lower dose of the secretagogue may be required.
## Monitoring
* **HbA1c:** Typically every 3–6 months.
* **Blood Glucose:** Periodic self-monitoring of blood glucose (SMBG).
* **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **Metabolism:** Linagliptin is the only DPP-4 inhibitor that does not require renal dosage adjustment, making it a preferred choice in patients with chronic kidney disease (CKD).
* **Administration:** May be taken with or without food.
* **Weight:** Considered weight-neutral.
* **Hypoglycemia:** Low risk of hypoglycemia when used as monotherapy; risk increases when combined with insulin or sulfonylureas.
***
*Disclaimer: This information is for educational purposes and does not constitute medical advice. Always verify current prescribing information, institutional protocols, and patient-specific factors with the latest resources (such as Lexicomp or DailyMed) before prescribing or administering medication.*
